Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

Product Sheet

IL-4/IL-13 Reporter 293 DDX35™ Cell Line

Catalog number: GM-C26021

Version 3.3.1.241024

Interleukin-4 (IL-4) is a cytokine essential for differentiating Th0 cells into anti-inflammatory Th2 cells. Secreted mainly by Th2 cells, IL-4 promotes B cell proliferation and IgE antibody synthesis, crucial in allergies. IL-4 activates downstream signaling pathways through receptor binding.

Similarly, IL-13 is produced by T cells, including Th2 cells, and shares biological traits with IL-4. Its complex signaling involves receptors like IL-13Rα1, activating downstream pathways.

The IL-4/IL-13 Reporter 293 DDX35™ cell line is a clonal stable 293 cell line with signal-dependent expression of a luciferase reporter gene, and it endogenously expresses IL-4Rα and IL-13Rα1. When IL-4/IL-13 binds to the receptor, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can block this signal transmission. The measurement of luciferase activity indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of a neutralizing antibody targeting IL-4 and IL-13.

The IL-4/IL-13 Reporter 293 DDX35™ cell line was obtained through extensive monoclonal screening and multiple rounds of monoclonal selection. It possesses high stability, high sensitivity, and high amplification properties, meeting the standards for customers' batch library construction and release experiments.


Anti-IL-4
Anti-IL-4R(12B5)
IL-4
IL-13
IL-4Rα
IL-13Rα1
JAK1
JAK2
TYK2
STATs
P
Luciferase

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

Specifications

Quantity	5E6 Cells per vial,1 mL
Product Format	1 vial of frozen cells
Shipping	Shipped on dry ice
Storage Conditions	Liquid nitrogen immediately upon receipt
Recovery Medium	DMEM+10% FBS+1% P.S
Growth medium	DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+0.75 μg/mL Puromycin
Note	None
Freezing Medium	90% FBS+10% DMSO
Growth properties	Adherent
Growth Conditions	37°C, 5% CO_2
Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.
Safety considerations	Biosafety Level 2
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

Materials

Reagent	Manufacturer/Catalogue No.
Puromycin	Genomeditech/GM-040401
Blasticidin	Genomeditech/GM-040404
Pen/Strep	Thermo/15140-122
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
DMEM	Gibco/C11995500BT
Recombinant Human IL-4 Protein	R&D SYSTEMS/204-IL/CF
Recombinant Human IL-13 Protein	Sino Biological/10369-HNAC
GMOne-Step Luciferase Reporter Gene Assay Kit	Genomeditech/GM-040503

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

Figures



Figure 1 | The passage stability of response to Recombinant Human IL-4 Protein. The passage 5, 10, 20, 25, 30 and 35 of IL-4/IL-13 Reporter 293 DDX35™ Cell Line (Cat. GM-C26021) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-4 Protein (R&D SYSTEMS/204-IL/CF) in assay buffer (DMEM+1% FBS+1% P.S) for 7 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). Data are shown by drug mass concentration.



Figure 2 | The passage stability of response to Recombinant Human IL-4 Protein. The passage 5 and 35 of IL-4/IL-13 Reporter 293 DDX35™ Cell Line (Cat. GM-C26021) at a concentration of 2E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-4 Protein (R&D SYSTEMS/204-IL/CF) in assay buffer (DMEM+1% FBS+1% P.S) for 7 hours, in triplicate. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). Data are shown by drug mass concentration.



Figure 3 | The passage stability of response to Recombinant Human IL-13 Protein. The passage 6, 11, 16, 26, 31 and 36 of IL-4/IL-13 Reporter 293 DDX35™ Cell Line (Cat. GM-C26021) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-13 Protein (Sino Biological/10369-HNAC) in assay buffer (DMEM+1% FBS+1% P.S) for 7 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). Data are shown by drug mass concentration.



Figure 4 | The passage stability of response to Recombinant Human IL-13 Protein. The passage 7 and 37 of IL-4/IL-13 Reporter 293 DDX35™ Cell Line (Cat. GM-C26021) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-13 Protein (Sino Biological/10369-HNAC) in assay buffer (DMEM+1% FBS+1% P.S) for 7 hours, in triplicate. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). Data are shown by drug mass concentration.



	IL-4/IL-13 Reporter 293 Cell Line
EC50	0.1142

Figure 5 | Response to Recombinant Human IL-4 Protein. The IL-4/IL-13 Reporter 293 DDX35™ Cell Line (Cat. GM-C26021) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-4 Protein (R&D SYSTEMS/204-IL/CF) in assay buffer (DMEM+1% FBS+1% P.S) for 7 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [171.9]. Data are shown by drug mass concentration.



	IL-4/IL-13 Reporter 293 Cell Line
EC50	0.007616

Figure 6 | Response to Recombinant Human IL-4 Protein. The IL-4/IL-13 Reporter 293 DDX35™ Cell Line (Cat. GM-C26021) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Human IL-4 Protein (R&D SYSTEMS/204-IL/CF) in assay buffer (DMEM+1% FBS+1% P.S) for 7 hours. The firefly luciferase activity was measured using the GMOne-Step Luciferase Reporter Gene Assay Kit (Cat. GM-040503). The maximum induction fold was approximately [171.9]. Data are shown by drug molar concentration.

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

Cell Recovery

Recovery Medium: DMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
e) Incubate the culture at 37°C in a suitable incubator. A 5% CO_2 in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a) Centrifuge at 176 x g for 3 minutes to collect cells.
b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
c) Aliquot 1 mL into each vial.
d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+0.75 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a) Subculturing is necessary when the cell density reaches 80%. It is recommended to perform subculturing at a ratio of 1:3 to 1:4 every 2-3 days. Ensure that the density does not exceed 80%, as overcrowding can lead to reduced viability due to compression.
b) Remove and discard culture medium.
c) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
d) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).
e) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
f) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

g) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

h) Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a) Upon initial thawing, a higher number of dead cells is observed, which is a normal phenomenon. Significant improvement is seen after adaptation. Once the cells reach a stable state, the number of dead cells decreases after subculturing and the cell growth rate becomes stable.

b) Ensure that the cell density does not exceed 80%, as overcrowding may lead to reduced viability due to compression.

Related Products

OX40	
H_OX40 Reporter Cell Line	Cynomolgus_OX40L CHO-K1 Cell Line
H_OX40 CHO-K1 Cell Line	H_OX40L CHO-K1 Cell Line
H_OX40L HEK-293 Cell Line	Anti-OX40L hIgG4 Reference Antibody(Amlbio)
Anti-H_OX40 hIgG2 Antibody(Ivuxolimab)	Anti-OX40L hIgG1 Reference Antibody(Oxebio)
Anti-OX40L hIgG4 Antibody(Amlitelimab)	Human OX40L Protein; mFc Tag
Biotinylated Human OX40L Protein; His-Avi Tag	Cynomolgus OX40 Protein; His Tag
Cynomolgus OX40L Protein; His Tag	Cynomolgus OX40L Protein; mFc Tag
Human OX40 Protein; His Tag	Human OX40L Protein; His Tag
IL-4/IL-13	
IL-4 Reporter Cell Line	IL-4/IL-13 Reporter 293 Cell Line
Cynomolgus_IL4R CHO-K1 Cell Line	H_IL4R CHO-K1 Cell Line
Anti-IL-4R hIgG1 Antibody(12B5)	Anti-IL4R hIgG4 Antibody（Dupilumab）
Anti-IL4R hIgG4 Reference Antibody (Dupbio)	
IL-31	
H_IL-31 Reporter Cell Line	Cynomolgus_IL31RA CHO-K1 Cell Line
H_IL31RA CHO-K1 Cell Line	H_IL31RA HEK-293 Cell Line
H_IL-31RA OSMR Baf3 Cell Line	Anti-OSMR hIgG4 Antibody(Vixarelimab)
Anti-IL31 hIgG1 Antibody(mAb33)	Anti-IL31RA hIgG1 Antibody(NA633)
Anti-IL31RA hIgG2 Antibody(Nemolizumab)	
TSLP:TSLPR	
H_TSLP Reporter Cell Line	H_TSLPR CHO-K1 Cell Line
Anti-H_TSLPR hIgG1 Antibody	Anti-TSLP hIgG2 Reference Antibody(Tezbio)
Anti-TSLP hIgG2 Antibody(Tezepelumab)	Human TSLP Protein; His Tag
Cynomolgus TSLP Protein; His Tag	
IL-5	

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

H_IL-5 Reporter 293 Cell Line	H_IL-5RA CHO-K1 Cell Line
H_IL-5RA HEK-293 Cell Line	Anti-IL-5R hIgG1 Antibody(Benralizumab)
Anti-IL5 hIgG4 Antibody(Reslizumab)	

Limited Use License Agreement

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.